Human Immunodeficiency Virus or HIV is a
harmful virus that can result in even taking the life of an individual
infected. HIV vaccine is an ultimate prevention and control strategy for AIDS.
The primary concept behind all HIV vaccines is to encourage the human immune
system to fight HIV. The vaccine could be effective in either of two ways
including “preventive” vaccine and “therapeutic” vaccines. Preventive HIV
vaccine is given to individual who do not have HIV, and therapeutic HIV vaccine
is given to individual who already have HIV. The goal of a therapeutic HIV
vaccine is to strengthen a patient’s immune response to the HIV that is already
in the patient’s body. Researchers are discovering the use of therapeutic HIV
vaccines to eliminate the need for antiretroviral therapy (ART) while still
keeping imperceptible levels of HIV and to slow down the progression of HIV
infection.
According to study, “Global
HIV Vaccines Market Size study, by Type (Acute Paronychia, Chronic
Paronychia, Candidal Paronychia, Pyogenic Paronychia), By Antibiotics
(Mupirocin Ointment, Fusidic Acid Ointment, Gentamicin Ointment, Dicloxacillin,
Others) and Regional Forecasts 2018-2025” the key companies operating in the
global HIV vaccines market are AlphaVax, Bionor Pharmaceuticals Asa, Antigen
Express, Crucell Pharmaceutical, Argo Therapeutic Inc., Genetic Immunity,
Celldex Therapeutics, GeoVax Labs, FIT Biotech, Immune Response Biopharma,
GeneCure LLC, Inovio Pharmaceuticals Inc., GenVec Inc., GlaxoSmithKline Plc.,
Novartis, Oncolys Biopharma, Janssen Global Services LLC, Profectus
Biosciences, PaxVax Corp., TVAX Biomedical, Sanofi.
Based on type, market is segmented into acute
paronychia, candidal paronychia, chronic paronychia and pyogenic paronychia. In
acute paronychia, the causative organisms are generally Staphylococcus aureus
or streptococci and, less commonly Pseudomonas or Proteus species. Based on
route of administration, market is segmented into oral administration,
intramuscular & subcutaneous administration and others. Based on
antibiotics, market is segmented into mupirocin ointment, gentamicin ointment,
fusidic acid ointment, dicloxacillin, and others. In addition, based on
application, market is segmented into research institutes and others.
The market is driven by increase in prevalence
of HIV infection due to prostitution, followed by rise in infectious diseases,
increase in expenditure on research & development (R&D), rise in
company initiatives to enhance vaccine research & development (R&D),
growth in non-governmental organizations to help the remote areas where
medicine cannot reach, rise in number of new entrants in the market and growth
in awareness among people about HIV. However, growth in number of trial failure
and expensive & multifaceted studies may impact the market. Moreover,
increase in number of new entrants and high growth prospects in emerging
markets are key opportunities for market.
Based on geography, the North-American is the
leading region in HIV vaccines market owing to presence of new technologies and
higher adoption of various HIV Vaccines trials in the region. The European and
Asian-Pacific regions are also estimated to witness higher growth rate due to
rise in prevalence of HIV diseases, growth in government support for vaccine
development and increase in healthcare sectors over the forecast period. It is
expected that the market will be reached at fast speed as a result of rise in
government initiatives to promote vaccines during the forecast period.
For more information, click on the
link below:
Contact Us:
Ken Research
Ankur Gupta, Head Marketing &
Communications
+91
9015378249
